Barclays’s Madrigal Pharmaceuticals MDGL Stock Holding History

Barclays’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-797	Closed	-$28K	–	6324
2015 Q3	$28K	Sell	797 -106	-12%	-$7.65K	﹤0.01%	5311
2015 Q2	$63K	Buy	903 +517	+134%	+$43.4K	﹤0.01%	5007
2015 Q1	$14K	Buy	386 +49	+15%	+$4.2K	﹤0.01%	6032
2014 Q4	$24K	Sell	337 -277	-45%	-$28.6K	﹤0.01%	6214
2014 Q3	$65K	Sell	614 -120	-16%	-$16.7K	﹤0.01%	5659
2014 Q2	$103K	Sell	734 -1,077	-59%	-$157K	﹤0.01%	5387
2014 Q1	$254K	Sell	1,811 -1,003	-36%	-$198K	﹤0.01%	4569
2013 Q4	$493K	Buy	2,814 +2,363	+524%	+$433K	﹤0.01%	4108
2013 Q3	$95K	Sell	451 -1,126	-71%	-$240K	﹤0.01%	5650
2013 Q2	$275K	Buy	+1,577	New	+$411K	﹤0.01%	4865

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

EULAV Asset Management Sarasota, Florida $2.77B AUM 18.47% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's MDGL Position: Q3 2026 in Review

Barclays increased its Madrigal Pharmaceuticals (MDGL) stake by 240% in Q3 2026, buying an estimated $6.95M and bringing the position to 18,642 shares worth $9.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Barclays first reported a position in MDGL in Q2 2013 and has held it in 54 quarters since. The position peaked at $25.5M in Q4 2022. 180 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Barclays held 18,642 shares of Madrigal Pharmaceuticals worth $9.39M as of Q3 2026.
Barclays bought 13,153 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $6.95M.
Madrigal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1679 holding.
Barclays first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 54 quarters since.
Barclays's Madrigal Pharmaceuticals position peaked at $25.5M in Q4 2022.
180 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.